One event. Multiple sources.
Health

New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

1 publisher first detected 2% of 46 Health publishers

Headline as filed by Wired.

Compare coverage — 1 report

Every publisher that filed on this event, earliest first, with each one's headline, summary, times and how long after the first report they filed.
Publisher Headline Summary Published Detected Delay Source Status
Wired New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
0m wired.com First

Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.

Reader comments

Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.

Nobody has commented on this story yet.

Add a comment

Up to 2,000 characters. Links are not accepted. Blank lines separate paragraphs.

In this story
Phase 8

Related coverage

connected by shared subjects